Cipla Limited — Q3 FY25 earnings call

Call held 28 Jan 2025

Management summary

Cipla reported its highest-ever quarterly revenue of ₹7,073 crores, up 8% YoY, and an all-time high EBITDA margin of 28% for Q3 FY25. Growth was robust across India, North America, Africa, and EMEU, with strong traction in branded prescriptions and Albuterol market share. However, launch delays for key US assets like Abraxane and ongoing supply issues for Lanreotide were noted. Management clarified that the Q3 margin is not sustainable for future quarters and provided updated FY25 guidance for EBITDA and ETR.

Highlights

  • Highest ever quarterly revenue of ₹7,073 crores, marking an 8% YoY growth.

  • All-time high EBITDA margin of 28%, driven by favorable mix and cost phasing.

  • Strong performance in key geographies: One India (10% YoY), One Africa (9% YoY USD terms), and EMEU (20% YoY USD terms).

  • Albuterol market share reached 21%, contributing to North America's $226 million quarterly revenue.

  • Goa facility cleared by US FDA with VAI Classification, derisking future launches.

Concerns

  • Lanreotide supply issues impacted revenue, though normalization is expected by end of Q4 FY25.

  • Abraxane launch delayed to H2 FY26 due to regulatory clearance and manufacturing ramp-up post-approval.

  • Q3 EBITDA margin of 28% is not sustainable for future quarters due to seasonal respiratory uptick and mix effects.

  • Virgonagar and Medispray facilities received 483 observations from US FDA, with official classification awaited.

Key financials

  1. Revenue ₹7,073 Cr +8%YoY
  2. EBITDA Margin 28% +1.8%YoY
  3. PAT ₹1,571 Cr
  4. R&D Investment ₹360 Cr
  5. R&D % of Revenue 5%
  6. Gross Margin 68% +1.7%YoY

What they filed

Q1 FY27: revenue up 0.6%, net profit down 33.8% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue4,775 4,971 4,798 5,046 5,226 +9%4,498 −10%4,210 −12%5,078 +1%
EBITDA1,438 1,662 1,319 1,624 1,523 +6%721 −57%567 −57%1,086 −33%
Net profit1,178 1,438 1,485 1,303 1,211 +3%617 −57%385 −74%862 −34%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • One India
    10% Revenue Growth
  • North America
    226 Mn Revenue
  • One Africa
    9% Revenue Growth10% Revenue Growth (INR)
  • EMEU
    20% Revenue Growth22% Revenue Growth (INR)

Capital allocation

high confidence
  • Capex Capex disclosed
    Between fiscal year '20 to year-to-date fiscal year '25, we have spent almost $100 million of CAPEX in these facilities.
  • Debt Net ₹466 Cr
    As of 31st December 2024, the debt on our balance sheet including lease liability stood at 466 crores with net cash equivalent balance of about 8,947 crores.
  • Liquidity Cash ₹8,947 Cr Healthy net cash position as of December 31, 2024.
    As of 31st December 2024, the debt on our balance sheet including lease liability stood at 466 crores with net cash equivalent balance of about 8,947 crores.

Guidance & targets

Profitability

  • EBITDA Margin Profitability · FY25 · High confidence higher than 24.5% to 25.5%

    Previously 24.5% to 25.5% → higher than 24.5% to 25.5%

    EBITDA for the year FY'25 is trending higher than our earlier guidance that we have given, which was 24.5% to 25.5%.

    — Ashish Adukia

Tax

  • Effective Tax Rate (ETR) Tax · FY25 · High confidence 27% to 28%
    We're guiding to 27%, 28% ETR for the full year.

    — Ashish Adukia

Shareholder Returns

  • Dividend Payout Ratio Shareholder Returns · ongoing · High confidence about 30%
    gradually we have increased our dividend in line with the profit increase and we have given guidance of about 30% to the market as well and we are sticking to that.

    — Ashish Adukia

Revenue

  • Top Line Growth Revenue · FY26 · Medium confidence grow
    In FY'26, we retain our guidance to grow our top line. We will further provide guidance on profitability once we finalize our budget.

    — Umang Vohra

R&D Spend

  • R&D % of Revenue R&D Spend · ongoing · High confidence 5% to 6%
    we retain our guidance of 5% to 6% as it actually gives us an opportunity to add more product programs to our pipeline.

    — Ashish Adukia

What to watch in Q4 FY25

Lanreotide Supply Normalization

by end of March / Q1 FY26
Current 50-60% of normal supply
Target 100% normal supply, full capacity from partner

Why it matters

Ensuring full supply of Lanreotide is crucial for recovering lost revenue and meeting market demand.

The business is on its way to resolve the supply issues related to Lanreotide and come back to normalized supply levels towards the end of Q4. ... we are probably about 50%, 60% there and what is not there is rapidly the partners rapidly working to bring that on line as well. So, our expectation right now is that the full capacity of the partner probably comes in, starts getting delivered pretty much from the end of March and so that allows us the ability to potentially see the ramp up in Q1 as also gives us the ability to build a little bit of inventory.

Risks & concerns

  • US FDA 483 observations at Virgonagar and Medispray facilities

    medium

    Virgonagar received eight 483 observations, Medispray received one; official classification awaited for both. Management is working on improving quality systems.

    During this quarter, the USFDA also inspected our manufacturing facility located in Virgonagar, Bengaluru and issued eight 483 observations. Official classification is awaited. During this month, we were also inspected at our Medispray facility by the US FDA and issued one 483 observation. Official classification of this facility is also made.

    Management acknowledged

  • Delays in key US product launches (Advair, Abraxane)

    medium

    Advair launch signaled for H2 FY26, Abraxane for H2 FY26, primarily due to pending regulatory approvals and manufacturing ramp-up post-approval.

    On Abraxane, we have a definite launch at least by the end of this next year and a few months after approval. I think the delays are largely due to regulatory clearance and filing and post that should follow.

    Management acknowledged

  • Lanreotide supply disruption impacting revenue

    medium

    Supply issues are being resolved, with normalization expected by end of Q4 FY25 and full capacity from partner by end of March.

    The business is on its way to resolve the supply issues related to Lanreotide and come back to normalized supply levels towards the end of Q4.

    Management acknowledged

  • Non-sustainability of Q3 EBITDA margin

    low

    The 28% EBITDA margin in Q3 was influenced by seasonal respiratory uptick and favorable mix, and is not expected to be consistent in future quarters.

    I don't think Cipla can do 28% EBITDA margins and that is what I mentioned because the question was with respect to quarter, whether you'd be able to do 28% EBITDA consistently and I said no, that's not a sustainable margin profile for us.

    Management acknowledged

Q&A highlights

5 direct, 1 evasive
US revenue trajectory and key product launches (Advair, Abraxane, Lanreotide, Revlimid) Partial
Revlimid is sequentially more or less the same. I think there's no increase in Revlimid quarter-on-quarter sequentially. On the rest of the assets, Advair, we have still not launched and we're signaling half two launch from the US facility. On Abraxane, we have a definite launch at least by the end of this next year and a few months after approval.

Clarifies the status and delayed timelines for critical US product launches, impacting future US revenue growth.

Asked by Saion Mukherjee

Impact of US President's comments on pharmaceutical tariffs Evasive
I think we can't comment specifically because I think we have to let the policy framework of the new administration set in. And whatever we're hearing right now is through the press and through media.

Management defers comment on a significant potential policy risk, indicating uncertainty and a wait-and-see approach.

Asked by Kunal Dhamesha

Sustainability of Q3 EBITDA margins and future guidance Direct
I don't think Cipla can do 28% EBITDA margins and that is what I mentioned because the question was with respect to quarter, whether you'd be able to do 28% EBITDA consistently and I said no, that's not a sustainable margin profile for us.

Management explicitly states that the high Q3 margin is not sustainable, managing investor expectations for future quarters.

Asked by Ankush Mahajan

Recovery timeline and capacity expansion for Lanreotide supply issues Direct
I think right now we are at roughly close to 40% to 50% of their overall index of 100 and we expect that by the end of March, we would be back to the 100. Right now, capacity expansion at the partner is a function of two things. It's a function of the capacity train, which is now in place.

Provides specific details on the current status and expected recovery timeline for a product facing supply disruptions.

Asked by Anubhav Agarwal

Reason for Abraxane launch delay despite Goa facility clearance Partial
One, we have to first get approval for the file. So, while Goa is cleared and the earlier intimation to us was that there is nothing pending in the file from an FDA perspective, we still have to get approval for it and I think obviously we are waiting for that approval.

Highlights that regulatory approval for the product file is still pending, even after facility clearance, contributing to launch delays.

Asked by Neha Manpuria

Strategy for capital allocation given significant cash reserves Direct
I think we see a lot of growth opportunities yet in many areas in India which is our core market and now we see some gaps in our portfolio which we want to address through acquisition in many forms, not just old company acquisition, but product acquisition, in-licensing, etc.

Outlines the company's strategic priorities for deploying its cash, focusing on inorganic growth in India and differentiated assets in the US.

Asked by Chirag

Timeline for Symbicort approval in the US Direct
I would say about we should be tracking within a period of 18 months.

Provides a specific, albeit broad, timeline for another key US inhalation product approval.

Asked by Nitin Agarwal

US FDA inspection issues and long-term solutions Direct
Structurally, how we are solving this is quality is a function of practice equipment and talent. And we have worked on all three of them. The more you can automate your equipment, the less there is a chance of any errors that happen, the more that you can build in sensitivity to your talent about how to do proper root cause investigations and observe your processes, the less you will have disruptions.

Addresses recurring regulatory concerns and outlines the company's comprehensive strategy to improve quality systems and compliance.

Asked by Chirag

2 min read 5 chapters

Detailed narrative

Strong Q3 FY25 Performance and Geographic Growth

Cipla delivered its highest-ever quarterly revenue of ₹7,073 crores, marking an 8% year-on-year growth. This was supported by robust performance across key geographies, with the One India business growing 10% YoY, One Africa achieving 9% YoY growth in USD terms (21% in ZAR terms for South Africa), and EMEU recording a strong 20% YoY growth in USD terms. The company's chronic mix in Branded Prescriptions improved to 61.5% as per IQVIA MAT December '24, and it added five brands with revenue over ₹100 crores, bringing the total to 26.

Record Profitability and Margin Expansion

The quarter saw an all-time high EBITDA margin of 28%, an increase of 184 basis points YoY and 138 basis points QoQ. Gross margin also improved to 68%, 166 basis points above the previous year, primarily due to overall mix change. Profit after tax stood at ₹1,571 crores, representing 22% of sales. However, management clarified that this 28% EBITDA margin is not sustainable for future quarters, attributing it to seasonal respiratory uptick and specific mix effects.

US Market Dynamics and Product Pipeline

North America delivered a quarterly revenue rate of $226 million, with Albuterol market share reaching 21%. Key US product launches, Advair and Abraxane, are now slated for H2 FY26, with Advair from the US facility and Abraxane from the Goa facility post-approval. The delays are primarily due to regulatory clearance and manufacturing ramp-up. The company also has a pipeline of two to three respiratory assets expected in 18-24 months and other peptide assets, aiming for a significant ramp-up in its US respiratory portfolio.

Regulatory Updates and Quality Initiatives

Cipla's Goa facility received a VAI Classification from the US FDA, a positive development. However, the Virgonagar and Medispray facilities were inspected, receiving eight and one 483 observations, respectively, with official classifications pending. Management emphasized its ongoing efforts to strengthen quality systems through improvements in practice, equipment, and talent to prevent future disruptions and ensure compliance.

Capital Allocation Strategy and Liquidity

The company maintains a healthy net cash position of ₹8,947 crores as of December 31, 2024, against a debt of ₹466 crores. Cipla aims to address portfolio gaps through acquisitions, product licensing, and in-licensing in India, and by acquiring differentiated assets in the US and other attractive markets. The R&D investment for the quarter was ₹360 crores, approximately 5% of revenue, with a guidance of 5-6% for the future to support pipeline development. The company also reiterated its commitment to a dividend payout ratio of about 30%.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls